A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

The primary purpose of the study is to determine the effect of mild, moderate, and severe hepatic impairment on the PK of total treprostinil palmitil (TP) and treprostinil (TRE) following a single dose of 80 micrograms (μg) TPIP, when compared to normal hepatic function.

NCT Number	NCT07643155
Lead Sponsor	Insmed Incorporated
Conditions	Hepatic Impairment
Enrollment	30 participants
Start Date	2026-06-10
Primary Completion	2027-02-07 (estimated)
Study Completion	2027-02-07 (estimated)
Updated on ClinicalTrials.gov	2026-06-11